Skip to search formSkip to main contentSkip to account menu

Varlitinib

An orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and… 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (1)

ARRY-334543
EGFR protein, humanInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pfizer lured by Array’s cancer know-how
NAture BIoteChNology | VOL 37 | AUGUST 2019 | 829–841 | www.nature.com/naturebiotechnology Eric Schmidt. PayPal’s co-founder… 
2019
2019
AB046. P-14. TREETOPP: a phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs)
2019
2019
AB063. P-34. A multicenter, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment naïve advanced or metastatic biliary tract cancer (BTC)
2018
2018
Abstract 3992: Varlitinib demonstrates tumor regression and vessel normalization in ErbB-dependent and mutated beta-catenin hepatocellular carcinoma patient-derived xenograft model
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and current therapies such as sorafenib, regorafenib and… 
2016
2016
Abstract 4719: Varlitinib demonstrates potent antitumor efficacy in patient-derived gastric cancer xenograft models
Varlitinib is a potent, reversible pan-HER inhibitor of the ATP-binding site of EGFR (IC50 = 7 nM), HER2 (IC50 = 2 nM) and HER4… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)